India, Oct. 19 -- Disc Medicine, Inc. (IRON) announced a proposed underwritten public offering of $350 million of its common stock and, for certain investors, pre-funded warrants to purchase common stock.
The financing comes on the same day the company reported positive Phase 3 APOLLO trial results for bitopertin, its lead treatment candidate for erythropoietic protoporphyria (EPP).
The offering remains subject to market conditions, and the company has not yet disclosed the final pricing or number of securities to be sold.
The company also intends to grant underwriters a 30-day option to purchase up to an additional $52.5 million in shares of common stock. All securities offered in the transaction will be sold by Disc Medicine.
Accordin...